Pheno Therapeutics Gains FDA IND Clearance for First-in-Class GPR17 Antagonist PTD802 in Multiple Sclerosis
Key Insights
The US FDA has cleared Pheno Therapeutics (search)' IND application for PTD802, a first-in-class selective GPR17 (search) antagonist designed to promote remyelination in multiple sclerosis (search).
PTD802 is the first GPR17 (search)-targeting program to receive IND clearance, establishing a new class of neuroprotective therapeutics.
A first-in-human clinical trial will evaluate the safety and tolerability of PTD802 in healthy volunteers, following prior CTA approval from the UK's MHRA in January 2025.
Pheno Therapeutics (search), a clinical-stage biotechnology company, has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for PTD802, a novel small molecule therapeutic targeting multiple sclerosis (search) (MS) through a remyelination approach. The regulatory milestone enables the company to proceed with a first-in-human clinical trial in the United States.
The FDA decision follows a clinical trial authorisation (CTA) granted by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) in January 2025, positioning Pheno Therapeutics (search) to advance its lead candidate into clinical evaluation on both sides of the Atlantic.
A First-in-Class Mechanism Targeting Remyelination
PTD802 is a selective antagonist of GPR17 (search) (G protein-coupled receptor 17), a receptor implicated in the regulation of oligodendrocyte precursor cell differentiation and myelination. By blocking GPR17, PTD802 is designed to promote remyelination — the repair of damaged myelin sheaths that insulate and nourish axons and nerve fibers in the central nervous system.
This mechanism represents a departure from currently available MS therapies, which primarily target the inflammatory component of the disease. In MS, the immune system attacks the myelin sheaths, leading to multifocal demyelination, axonal injury, and neurodegeneration. Despite the ability of existing drugs to control inflammation, the disease can progress to total physical and cognitive disability.
PTD802 is the first GPR17 (search)-targeting program to receive IND clearance, delivering what Pheno Therapeutics (search) describes as a new class of neuroprotective therapeutics. The company noted that this development also supports its intellectual property position in the United States.
Clinical Development Strategy
The first-in-human study will investigate the safety and tolerability of PTD802 in healthy volunteers. The trial design reflects a standard early-phase approach for establishing the foundational clinical profile of a novel therapeutic candidate before advancing to patient populations.
PTD802 was developed under an exclusive worldwide license from UCB (search), the global biopharmaceutical company.
Leadership Commentary
"FDA IND clearance is an important milestone for our PTD802 programme and a step further toward our ultimate goal of providing an effective treatment for neurological diseases associated with demyelination," said Dr. Fraser Murray, CEO of Pheno Therapeutics (search). "As the first company to gain approval to begin clinical trials for a selective GPR17 (search) antagonist, we are proud to be leading the way and believe this approach has the potential to offer real patient benefit, in MS and beyond."
The company's focus on remyelination addresses a significant gap in the MS treatment landscape, where existing therapies have demonstrated efficacy in reducing relapse rates and inflammatory lesion burden but have shown limited impact on halting or reversing progressive disability driven by neurodegeneration.